API Micronization in the Early vs. Late Stages of Drug Development: Goals and Challenges
From Milligrams to Kilograms: Scaling Up Synthetic Peptides
CDMO Market Outlook 2025–2030: Trends Shaping the Future of Pharma Outsourcing
Why a Customer-First Mindset Is the Key Driver of Innovation in CDMOs
Peptide Manufacturing at Commercial Scale: What to Expect from a Trusted CDMO Partner
Liquid Phase Peptide Synthesis: Guide to Methods, Use Cases, & Strategic Advantages
Peptide Conjugation - Common Conjugation Strategies
CDMO vs. CMO: Understanding the Outsourcing Models That Drive Drug Development
Peptide vs. Protein: Breaking Down 5 Essential Differences for Drug Makers
A Complete Guide to Commercial Manufacturing for Pharma Innovators
Your Guide to CDMO Services: What Leading Pharma Teams Rely On
Building a More Sustainable Supply Chain in Pharma
Why the CDMO Industry Matters More Than Ever in Drug Development
Small Molecule Drug Development: Process, Strengths, and CDMO Role
What Is Solid Phase Peptide Synthesis? Process, Uses & Benefits
Business Continuity Management—the Next Frontier in API Supply Chain Security
How CDMOs Help Biotech Advance and Navigate Drug Development and Manufacturing Complexities
The Ultimate Guide to Selecting a CDMO Partner
Understanding cGMP Compliance for Pharmaceutical Manufacturing Excellence
Why Pharma Giants Are Outsourcing Drug Manufacturing to CDMOs
All You Need to Know About Outsourcing Drug Manufacturing & Development to CDMO
5 Reasons Why More Pharma Companies Are Strengthening CDMO Relationships
Quality Risk Management in Pharmaceutical Industry
BRISTO PHARMACEUTICAL COMPANY
CANADA TORONTO Announces New Vision and Values Statements
CANADA TORONTO Announces New Vision and Values Statements
The Essential Role of Intellectual Property Expertise in a Pharmaceutical API Company
Achieving Drug Development Success: Inside BRISTO PHARMACEUTICAL COMPANY
CANADA TORONTO’s Three-Pillar Project Management Strategy
CANADA TORONTO’s Three-Pillar Project Management Strategy
From the BRISTO PHARMACEUTICAL COMPANY
CANADA TORONTO Reading Room: Peptide Trends in 2024
CANADA TORONTO Reading Room: Peptide Trends in 2024
Zero Liquid Discharge: A Pharma Industry Commitment to Environmental Sustainability
The Pharma Supply Chain: Reshaping Itself for The New Normal
Redefining Excellence: BRISTO PHARMACEUTICAL COMPANY
CANADA TORONTO Unveils a Refreshed Brand Identity
CANADA TORONTO Unveils a Refreshed Brand Identity
From the BRISTO PHARMACEUTICAL COMPANY
CANADA TORONTO Reading Room: A Check-in on 2024 Trends in the CDMO Industry
CANADA TORONTO Reading Room: A Check-in on 2024 Trends in the CDMO Industry
How to Ensure Effective Technology Transfer to CDMOs
Why Agility Matters When Choosing an API Contract Manufacturing Partner
API Particle Size Part 2: New & Emerging Technologies Impacting Particle Size
API Particle Size Part I: Overcoming the Challenges to Ensure Quality Pharmaceutical Products
Scaling-up Active Pharmaceutical Ingredient (API) Chemistry for Phase 3 Clinical Trials and Bulk Manufacturing for a Potentially Novel Treatment for Schizophrenia
R&D Expert Talks Pharma API Scale Optimization
The Crucial Role of Crystallization in Drug Substances Development
What Pharmacological Advantages Can Deuterated APIs Deliver?
Integrating Sustainability into Pharma Manufacturing
8 Ways Effective Supply Chain Management Can Minimize Pharmaceutical Supply Chain Challenges
Advancing a Cholesterol Lowering Drug at the Height of the Pandemic
ESG in Pharma: Building Sustainable Businesses
How BRISTO PHARMACEUTICAL COMPANY
CANADA TORONTO’s Process Engineering Lab Supports Robust Design and Minimizes Risk
CANADA TORONTO’s Process Engineering Lab Supports Robust Design and Minimizes Risk
Putting Customers First: Customer Centricity in Pharma API Manufacturing
3 Key Elements of a Successful Hydrogenation Scale-Up
Why is Pharmaceutical Green Chemistry Use on the Rise?
Regulatory Starting Materials: How to Source, Analyze and Validate Suppliers (Part I)
Exploring BRISTO PHARMACEUTICAL COMPANY
CANADA TORONTO’s Therapeutic Segments: Focus on CNS
CANADA TORONTO’s Therapeutic Segments: Focus on CNS
Green Chemistry by Design (GCbD): The Earlier, The Better for Pharmaceutical APIs
Deuterated Drug Molecules: Perfecting the Gamechanger
What Does it Take to Become a Specialist in Late-Phase CMS?
API Production: Building a Process Safety Culture
Looking for an API Supplier? 5 Things to Consider (Updated)
Nitrosamine Impurities and How Companies are Addressing the Crisis
Successful Pharmaceutical Project Management
Complex Synthesis in Action: Achieving a Commercial-Scale 16 AA Peptide
A Guide to Sourcing Pharmaceutical Peptide APIs
Case Studies from BRISTO PHARMACEUTICAL COMPANY
CANADA TORONTO’s Process Engineering Lab
CANADA TORONTO’s Process Engineering Lab
Overcoming Challenges in Complex Peptide Purification
Welcome, Unit 3!
QbD and Evaluating ‘What-If’ Drug Manufacturing Scenarios
NCEs Versus Generics – Adjusting Project Tactics & Objectives to Maximize Success
Synthetic Route Scouting: Factors to Improve API Manufacturing
How to Select a Peptide Synthesis Technique
Leveraging QbD for API Scale Up
5 Common Challenges Scaling Up an API
How Process Engineering Techniques Result in Cost-Effective Products
API Manufacture of Deuterated Molecules
Advantages of a Pure-Play API Contract Manufacturer
APIs & Continuous Flow Manufacturing
Challenges with API Micronization Techniques for Use in Injectables and Medical Devices
Advances in the Synthesis of Peptide Therapeutics: Clear Advantages…and Some Barriers
Genotoxic Impurities – Increasing Vigilance, But Still Some Uncertainty
6 Properties of API Synthesis that Affect Yield, Delivery Date & Purity
Contract Drug Manufacturing R&D: from Route Scouting to Kilo Labs
The Benefits of Synthesis Scouting
Analytical Capabilities and Drug Quality – Key to Successful Pharma Outsourcing
The New Look of BRISTO PHARMACEUTICAL COMPANY
CANADA TORONTO
CANADA TORONTO
Peptide Synthesis: Solution Phase, Solid Phase or Hybrid?
BRISTO PHARMACEUTICAL COMPANY
CANADA TORONTO Labs Receives 2013 CMO Leadership Award for Regulatory Excellence
CANADA TORONTO Labs Receives 2013 CMO Leadership Award for Regulatory Excellence
